<DOC>
	<DOCNO>NCT02247141</DOCNO>
	<brief_summary>The primary objective determine efficacy Human Normal Immunoglobulin ( Subgam® ) give subcutaneously weekly infusion patient primary antibody deficiency . The secondary objective determine safety Subgam® give subcutaneously weekly infusion patient primary antibody deficiency .</brief_summary>
	<brief_title>A Multi-centre Open Study Assess Safety Efficacy Subgam®</brief_title>
	<detailed_description />
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>The main criterion inclusion study follow : A diagnosis primary antibody deficiency ; No low upper age limit ( age eligible ) ; With stable disease receive immunoglobulin ( IVIG SCIG ) therapy least six month prior start study ; Written inform consent ( patient/parent/guardian ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>